Illumina, Inc. (NASDAQ: ILMN) announced today that Magistrate Judge Elizabeth D. LaPorte of the U.S. District Court for the Northern District of California granted a motion for summary judgment of invalidity filed by Complete Genomics, Inc. against certain claims of Illumina’s U.S. Patent No. 6,306,597. Over Illumina’s objections, the Court found that these claims were not novel over the prior art. The summary judgment ruling did not address a number of additional patent claims being asserted by Illumina against Complete Genomics that were not the subject of the validity motion.
Jay Flatley, Illumina’s President and Chief Executive Officer, stated, “We strongly disagree that any of the claims of our patent are invalid, and we intend to appeal the Court’s ruling. We believe that this patent covers important and novel inventions that Complete Genomics has misappropriated.” Illumina also continues to vigorously protect its rights under a second patent that Illumina more recently asserted against Complete Genomics in the U.S. District Court for the Southern District of California.
Illumina ( www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.Forward-Looking Statements This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.